ZVRA241220P16000
- 0.00
- 0.000.00%
Zevra Therapeutics Newsroom
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $20
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $25
Zevra Therapeutics: Strong Financials, Strategic FDA Approval, and Growth Prospects Drive Buy Rating
Zevra Therapeutics Is Maintained at Buy by Canaccord Genuity
Zevra Therapeutics Price Target Cut to $23.00/Share From $25.00 by Canaccord Genuity
Zevra Therapeutics Analyst Ratings
CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $23
Roth MKM Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $21
Zevra Therapeutics (ZVRA) Receives a Buy From Roth MKM
William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
Zevra Therapeutics: Strong MIPLYFFA Launch and Strategic Investments Justify Buy Rating Despite OLPRUVA Challenges
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating
Buy Rating Affirmed for Zevra Therapeutics Based on Strong NPV and Future Market Potential
Guggenheim Initiates Zevra Therapeutics(ZVRA.US) With Buy Rating, Announces Target Price $20